Quick search
Advanced search in
Field to searchTerm
Farmeconomia. Health economics and therapeutic pathways
Add rule
Filters (1 )
  • Access Mode (1)
    Clear
  • Research Type (4)
    Clear
  • Type (2)
  • Language (2)
  • Community (1)
  • Content Provider (14)
  • Access Mode (1)
    Clear
  • Research Type (4)
    Clear
  • Type (2)
  • Language (2)
  • Community (1)
  • Content Provider (14)
Download Results
299 research outcomes, page 1 of 30
  • publication . Article . 2020
    Open Access English
    Authors:
    Cortesi, Paolo Angelo; Cozzolino, Paolo; Capra, Ruggero; Cesana, Giancarlo; Mantovani, Lorenzo Giovanni;
    Publisher: SEEd Medical Publishers

    INTRODUCTION: Poor specific economic information are available for the different Multiple Sclerosis (MS) courses: relapsing remitting (RRMS), secondary progressive (SPMS) and primary progressive (PPMS). This study aims to fill this gap.METHODS: A cost of illness study w...

  • publication . Article . 2020
    Open Access English
    Authors:
    Roggeri, Daniela Paola; Zanon, Ezio; Biasoli, Chiara; Roggeri, Alessandro;
    Publisher: SEEd Medical Publishers

    Prophylaxis is recognized as the most effective treatment regimen for patients with severe hemophilia A. Prophylaxis with standard half-life (SHL) FVIII products requires frequent intravenous administrations, at least two-three times per week. Frequency of injections is...

  • publication . Article . 2012
    Open Access English
    Authors:
    Gasparini, Roberto; Panatto, Donatella; Dirodi, Bruna; Prato, Rosa; Amunni, Gianni; Turello, Valter; Sudano, Luigi; Cristoforoni, Paolo; Boccalini, Sara; Bonanni, Paolo;
    Publisher: SEEd Medical Publishers

    In Valle d’Aosta region 89% of women (aged 24-64) are screened regularly, meaning every 3 years. The analysis on cross-protective activity exercised by bivalent and quadrivalent vaccines shows that the bivalent vaccine could prevent more pre-cancerous lesions and cases ...

  • publication . Article . 2018
    Open Access English
    Authors:
    Bandi, Ombretta;
    Publisher: SEEd Medical Publishers
  • publication . Article . 2020
    Open Access
    Authors:
    Povero, Massimiliano; Pradelli, Lorenzo;
    Publisher: Seed SRL

    <jats:p>INTRODUCTION: Anti-TNF-α biosimilars (ATB) hold the promise of reducing costs leading in improving access to bio-logical therapies. There is limited insight into how the savings generated by biosimilars may translate into patient benefit in other disease areas.A...

  • publication . Article . 2011
    Open Access
    Authors:
    Luca Degli Esposti; Silvano Adami; Giovanni Iolascon; Alfredo Nardi; Luca Pietrogrande; Giuseppina Resmini; Maurizio Rossini; Umberto Tarantino; Paolo Tranquilli Leali; Carlo Trevisan; ...
    Publisher: Seed SRL

    <jats:p>The objectives of the present study were to calculate the cost of illness of osteoporosis and to assess drug utilization patterns in postmenopausal women after a fracture-related hospitalization. The study subjects were enrolled from a large population-based adm...

  • publication . Article . 2006
    Open Access English
    Authors:
    Venditti, Mario; Pompeo, Maria Elena; Fabi, Flavia;
    Publisher: SEEd Medical Publishers

    <jats:p>Tigecycline is a new first-in-class glycylcycline antimicrobial agent with expanded broad-spectrum activity. It was developed to overcome the two key resistance mechanisms, efflux pumps and ribosomal protection, that limit the use of tetracycline. The spectrum o...

  • publication . Article . 2011
    Open Access English
    Authors:
    Giampiero Mazzaglia; Alessandro Filippi; Lorenzo G. Mantovani; Gianluca Furneri; Carlo Niccolai; Jacopo Cricelli; Achille P. Caputi; Ovidio Brignoli; Claudio Cricelli;
    Publisher: SEEd Medical Publishers
  • publication . Article . 2008
    Open Access
    Authors:
    Maria Caterina Cavallo; Filippo Cipriani; Simone Gerzeli; Nadia Demarteau; Alessia Marocco; Francesco Bamfi;
    Publisher: Seed SRL

    <jats:p>In Lazio region 57,3% of women (aged 25-64) are screened regularly, meaning every 3 years. Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 104 cases of cervicocarcinoma and 43 rela...

299 research outcomes, page 1 of 30
Last index information